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 Recombinant human erythropoietin (rHuEpo) has been shown to be effective in improving anemia in 
a proportion of cancer patients. The response rate is around 60 % but varies considerably according to 
baseline hematocrit and transfusion needs, as well as the response criteria used. Response is not greatly 
influenced by the type of tumor, except in situations of major marrow involvement and limited residual 
hematopoiesis, or in the presence of specific mechanisms of anemia, such as hemolysis, splenomegaly, 
bleeding, hemodilution, or ineffective erythropoiesis. Stem cell damage by previous therapy as well as 
marrow suppression by current intensive chemotherapy can impair response. Besides its intensity, the type of 
chemotherapy may not be critical, although patients undergoing platinum-based chemotherapy may respond 
faster than those receiving non-platinum regimens. Complications such as infections, bleeding or nutritional 
deficiencies may have a major negative impact on outcome. An important response-limiting factor is 
functional iron deficiency, i.e. an imbalance between iron needs in the erythropoietic marrow and iron 
supply, which depends on the level of iron stores and its rate of mobilization. Functional iron deficiency is 
best monitored by the percentage of hypochromic red cells, and oral or intravenous iron supplements should 
be given when this percentage rises above 10 %. All these factors explain why the response rate is only about 
60 %. Therefore, it would be interesting to develop models that could help predict response to rHuEpo, in 
order to select the most appropriate cancer patients for this therapy. Few baseline parameters have been 
shown to be highly predictive of response in patients with solid tumors, although most studies in patients 
with myeloma or lymphoma have indicated that patients with a low baseline serum Epo level will respond 
better. Early changes after 2 to 4 weeks of treatment are also of great interest. Among these early changes, 
increments of serum transferrin receptor (sTfR), reticulocytes and hemoglobin, as well as the persistence of 
elevated ferritin or Epo levels, have all shown some predictive value. Combination of baseline serum Epo 




 Many patients with neoplastic disease develop anemia, irrespective of whether they are suffering 
from solid tumors or hematological malignancies 1-3. Clinical studies have shown that recombinant human 
erythropoietin (rHuEpo) therapy can ameliorate the anemia associated with cancer and chemotherapy, reduce 
the need for transfusions and possibly improve the quality of life 4. A decrease in transfusion requirements is 
the major objective of rHuEpo therapy, reducing the cost, inconvenience, and potential adverse effects of 
blood transfusions. However, large doses are generally required and many patients do not respond even to 
very high doses of rHuEpo. It is therefore important to be able to recognize and possibly correct conditions 
adversely affecting response to rHuEpo. When no such particular condition can be identified, it would also 
be of great interest to have at one’s disposal predictive algorithms of response, so that patients very likely to 
respond can be selected for therapy and prolonged ineffective use of an expensive medication can be avoided 
in those patients with a low probability of response. 
 
 
Mechanisms of the anemia of cancer 
 
 The pathogenesis of the anemia of cancer is multifactorial 1-3. A number of causes are frequently 
present and it is therefore difficult to identify a single causative factor in individual patients. Red cell loss 
may result from hypersplenism, blood losses consecutive to hemorrhage or iatrogenic phlebotomy, and 
autoimmune or microangiopathic hemolysis. Red cell production may be diminished by bone marrow 
infiltration, marrow necrosis, hemophagocytosis, myelofibrosis, deficiency of erythropoietic cofactors (folic 
acid, vitamin B12, iron), or infections. These mechanisms of anemia are much more prevalent in 
hematologic malignancies, but it is always important to identify them because specific therapeutic 
intervention can often be effective.  
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 However, the so-called « anemia of chronic disorders » (ACD) has been found to play a major role in 
the pathogenesis of cancer-associated anemia. ACD is characterized by inadequate production of 
erythropoietin, inhibition of the proliferation of erythroid progenitor cells in the bone marrow and 
disturbances of iron utilization 5. In cancer patients, a number of immunomodulatory peptides (cytokines), 
such as interleukin-1 and tumor necrosis factor, are produced and released by macrophages and other cells 
and appear to be involved in the pathogenesis of ACD 6.  
 Anemia in cancer patients can also be caused or aggravated by therapy with antineoplastic agents. In 
particular, treatment with platinum, but not with other chemotherapeutic agents, has been associated with 
impairment of erythropoietin production 7.  
 
 
Design of therapy 
 
 The rate of response to rHuEpo in patients with cancer vary widely among published studies. This is 
due in part to differences in disease- and treatment- related factors, but this also reflects large differences in 
dose, frequency and route of administration, duration of therapy and the response criteria used. There is a 
clear dose-response effect with rHuEpo and most studies in cancer patients have used doses in the range of 
300-900 U/kg/wk, well above those given to renal failure patients. The more convenient subcutaneous route 
of administration has been shown to ensure more favorable pharmacokinetics 8 that translates into higher 
efficacy 9 in renal failure patients. Most trials administered rHuEpo thrice weekly, a schedule demonstrated 
to be more efficient than daily injections in normal subjects 10, but it remains to be shown whether weekly 
injections are as effective. The duration of treatment is of critical importance. Whereas there was no 
significant difference in the rate of transfusions between placebo and rHuEpo-treated patients during the first 
month of therapy, the difference became highly significant during the second and third months of treatment 
4
. This is due to the fact that expansion of the erythropoietic marrow in response to rHuEpo is very gradual 
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and achieves maximum activity only after several weeks of treatment 11. The response rate can thus be 
further improved when patients are treated for 6 months or more 12.  
 The criteria used for defining response are determinant in the final evaluation of efficacy. It is 
obvious that trials employing less stringent response criteria will report better outcome. The patient’s 
hematologic parameters at baseline are also of importance. Patients with more severe anemia and more needs 
for transfusion probably have a lower probability of achieving a target hematocrit. Pretreatment hematocrit 
was an important factor when rHuEpo was given for the prevention of anemia 13 but no longer when it was 
given after anemia was well established 14. This has been very well illustrated in animal studies in which 
rHuEpo was much more "efficient" when it was started before the administration of 5-FU because it could 
then increase the hematocrit better while myelosuppression was not yet occurring 15. Uniform response 
criteria can thus be proposed for transfused and untransfused, severely or not severely anemic cancer patients 
(table 1). Complete response is defined by normalization of the hematocrit, major response by the abolition 
of transfusion needs and an hematocrit increment greater than 6 percentage points and achievement of an 
hematocrit higher than 30 %, while minor response corresponds to only one of the two last criteria or a 
reduction of transfusion requirements by at least 50 %. When rHuEpo is given to prevent anemia during 
chemotherapy, complete response can be defined by maintenance of a normal hematocrit, major response by 
a drop of the hematocrit by less than 6 percentage points, and minor response by a larger drop in hematocrit 
but without need for transfusion. 
 
 
Factors influencing response 
 
 It is thus clear that a number of disease- and treatment- related factors may influence response to 
rHuEpo. Except when there is major invasion by cancer cells and limited residual normal hematopoiesis, 
marrow involvement by the tumor does not appear to limit the efficacy of rHuEpo 4,16. The type of tumor has 
generally not influenced the response rate, provided that no other specific mechanism of anemia is at work. 
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Patients with multiple myeloma or low grade lymphoma apparently have similar response rates 17,18. 
Although there were no apparent differences between hematologic and non-hematologic malignancies in the 
largest study published 4, there has been a suggestion that patients with breast or colon cancer 19 but not 
those with squamous cell carcinoma 20 may respond less well than patients with myeloma.  
 Stem cell damage by previous chemotherapy should considerably interfere with response to rHuEpo, 
but curiously this has not been studied so far. However, the poorer response obtained in patients with lower 
platelet counts may in fact just indicate that 17,18. For patients treated concomitantly with chemotherapy, 
there is no marked difference between those receiving platinum-based regimens 21,22 and those receiving 
other forms of chemotherapy 17,18,23. In the largest study published 4, patients receiving platinum-based 
chemotherapy responded more rapidly than those receiving other combinations but the overall response rate 
was similar in the 2 groups. However, dose intensity of the two forms of chemotherapy was not assessed and 
it is therefore impossible to compare the degrees of myelosuppression induced by chemotherapy and thus the 
capacity of rHuEpo to overcome it. Patients receiving chemotherapy of moderate intensity respond as well as 
those not receiving concomitant chemotherapy 4. It is however probable that more intensive chemotherapy 
regimens would be associated with lower response rates. 
 Complications of chemotherapy, such as inflammation, infections, nutritional deficiencies or 
bleeding, may have a negative impact upon response 24. Functional iron deficiency is a major factor limiting 
the efficacy of rHuEpo therapy. It is defined as an imbalance between iron needs in the erythroid marrow and 
iron supply which depends on the level of iron stores and its rate of mobilization. This may occur even in the 
presence of large iron stores when storage iron release is impaired, as it is the case in the anemia of chronic 
disorders 25. Functional iron deficiency is best diagnosed by a percentage of hypochromic red cells greater 
than 10 % 26, a parameter calculated by some automated hematologic cell counters. Alternatively, it can also 
be suspected when transferrin saturation falls below 15 %. Because there is some concern that tumor cells 
may need iron for optimal growth 27, routine iron supplementation of all cancer patients receiving rHuEpo is 
not recommended, except when absolute iron deficiency is present, i.e. when serum ferritin is below 12 
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µg/L. Otherwise, iron supplements can be given when the percentage of hypochromic red cells is greater 





 As the response rate appears to vary considerably among patients treated similarly, it would be 
interesting to identify possible prognostic factors of response. Because clinical efficacy cannot be assessed 
before weeks of treatment, identification of early predictors of response could help provide the benefits of 
rHuEpo therapy to as many anemic cancer patients as possible while avoiding prolonged ineffective use of 
an expensive medication.  
 This has first been proposed in patients with the anemia of renal failure 28. The best prediction by 
baseline parameters only was obtained with pretreatment soluble transferrin receptor (sTfR) and fibrinogen : 
there was a 100 % response rate when both were low, versus only 29 % when there were both high, and 67 
% when one was low and the other high. Changes of sTfR after 2 weeks of treatment were also predictive 
(table 2). When the 2-week sTfR increment was ≥ 20 %, the response rate was 96 %. When sTfR increment 
was < 20 %, the response rate was 100 % when baseline sTfR was low and fibrinogen normal, 12 % when 
baseline fibrinogen was elevated and 62 % when baseline fibrinogen was normal but baseline sTfR high. 
These prognostic factors illustrate the importance of the early erythropoietic response (changes of sTfR 
levels), subclinical inflammation (fibrinogen) and functional iron deficiency (baseline sTfR). 
 
 In cancer patients, much attention has been paid to the possible value of baseline serum Epo because 
it was thought that patients would respond better if they had a defect in their capacity to produce Epo as 
compared to those whose anemia was accompanied by adequate serum Epo levels. Studies in patients with 
solid tumors have failed to confirm any predictive value of baseline Epo even when Epo deficiency was 
demonstrated in all or part of the patients 4,22,29,30. As Epo levels must be interpreted in relation to the degree 
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of anemia, the ratio of observed to predicted Epo levels (O/P ratio) represents a better assessment of the 
adequacy of Epo production 31. In patients with hematologic malignancies, it has been observed that low 
baseline serum Epo levels 14 or decreased O/P ratio 23 were associated with a significantly lower probability 
of response. This has been confirmed in large multicenter trials in patients with multiple myeloma or non-
Hodgkin’s lymphoma 17,18. An O/P ratio < 0.9 was found to be associated with high response rates, whereas 
patients with an O/P ratio > 0.9 rarely benefited from therapy 32. 
 As many in vitro and animal studies have demonstrated that several cytokines, including IL-1, TNF-
α, and IFN-γ, strongly inhibited normal erythropoiesis and that this effect can be overcome only with large 
doses of rHuEpo, Ludwig 14 examined the possible predictive values of serum levels of these cytokines, but 
the results were disappointing. This is not entirely surprising since serum levels of these cytokines may not 
be relevant, whereas local intramedullary levels may be much more important but non-evaluable. 
 As compared to baseline parameters, early changes observed after 2 weeks of treatment could be 
more informative. A rapid elevation of hemoglobin levels often predicted a good probability of later 
response 14,18,33. An increase of reticulocyte counts by ≥ 40,000/µl from baseline to week 2 or 4 appeared to 
be predictive of response but its discriminative power was weak 33. In several studies, hematologic response 
to rHuEpo was strongly associated with early increases of sTfR levels after 1-2 weeks of treatment 23,30,32. 
Ludwig 14 conducted the most thorough analysis and found that increases of hemoglobin, sTfR and 
reticulocytes, as well as decreases of serum Epo, ferritin, iron, C-reactive protein or neopterin after 2 weeks 
were all correlated with response.  
 
 Various models have sought to combine the predictive power of several parameters. In a study 
including equal numbers of patients with solid tumors or hematologic malignancies 14, if after 2 weeks of 
therapy Epo was > 100 mU/ml and hemoglobin had not increased by at least 0.5 g/dL, there was a 94 % 
probability of unresponsiveness; otherwise response was likely in 80 % of the patients (table 3). If serum 
Epo was < 100 mU/ml and hemoglobin concentration had increased by ≥ 0.5 g/dL, the probability of 
responses was 100 %; otherwise the probability of failure was 62 %. However, 34/80 patients did not fall 
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into any of these two categories and thus prediction was valid only in a little more than half of them. The 
predictive value of a decrease in serum Epo levels may have two explanations. Endogenous serum Epo could 
decrease as the hematocrit rose in responders, but the magnitude of the hematocrit changes by 2 weeks 
seemed to be too small. Erythropoietin appeared to accumulate in non-responders but it cannot be excluded 
that these patients were receiving more intensive chemotherapy than others and thus be more likely to have 
inappropriate increases of endogenous serum Epo values 34. On the other hand, Epo could be utilized by the 
stimulated marrow, but this has been contradicted by many experimental data 35,36. Alternatively, a serum 
ferritin value ≥ 400 ng/ml after 2 weeks predicted for failure in 88 % of the cases, whereas serum ferritin 
levels < 400 ng/ml predicted for success in 72 % of the cases. However, the specific cutpoint of 400 ng/ml 
cannot be extrapolated to other patients because it depends so much on the previous transfusion history.  
 In a subset of patients from a large multicenter study 4, some prediction of response could be derived 
from changes observed in reticulocytes and hemoglobin from baseline to week 2 of therapy 33. Among 
patients not receiving chemotherapy (table 4), the response rate was poor when the 2-week increment of 
hemoglobin level was < 0.5 g/dL, but it was excellent when the hemoglobin level or reticulocyte count 
increased by ≥ 0.5 g/dL or ≥40,000/µL, respectively. The predictive power of these parameters was much 
less substantial when the hemoglobin increased by ≥ 0.5 g/dL but the reticulocyte elevation was smaller. 
Adequate prediction of response could not be provided on the basis of hemoglobin and reticulocyte changes 
in patients receiving concomitant chemotherapy (table 5). Although some improvement in forecast could be 
obtained in patients increasing their hemoglobin by ≥ 1 g/dL after 4 weeks of treatment, predicting response 
on the basis of the response itself may appear to be trivial. 
 A combination of baseline parameters and early changes observed after 2 weeks of rHuEpo may 
provide another useful approach. Among evaluable patients treated in a large multicenter study 18, the failure 
rate was almost 90 % when baseline serum O/P Epo was higher than 0.9 or when serum O/P Epo was less 
than 0.9 but the hemoglobin increment by week 2 was <0.3 g/dL (table 6). On the other hand, the success 
rate was around 90 % when baseline serum O/P Epo was less than 0.9 and hemoglobin increased by ≥ 0.3 
g/d. In another large single center study 32, the combined use of baseline serum Epo and the 2-week 
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increment of sTfR proved to be very powerful (table 7). Only 18 % of patients with a baseline serum Epo 
greater than 100 mU/ml responded to treatment, and only 29 % responded when the baseline serum Epo was 
< 100 mU/mL but the 2-week sTfR increment was less than 25 %. On the other hand, the response rate was 





 In conclusion, a number of simple algorithms have been proposed to help predict outcome of 
treatment with rHuEpo. These algorithms were generally based on a combination of the adequacy of baseline 
endogenous Epo production and early direct (changes in hemoglobin, reticulocytes or sTfR) or indirect 
(changes in serum Epo or ferritin) indicators of erythropoietic marrow response. These models should help 
ensure a better use of rHuEpo by providing it to as many anemic cancer patients as possible but only to those 
with an excellent chance of success. Some models underscore sensitivity and this permits to treat all 
potential responders. Other models give emphasis to specificity so that most failures can be predicted and 
rHuEpo therapy can be avoided or stopped early. Several of them achieve an overall accuracy of about 90 %. 
The respective value of these various algorithms remains to be confronted in a prospective study. However, 
the occurrence of complications such as infections or functional iron deficiency cannot be predicted as well 
and one should always monitor patients for their occurrence even when the probability of response was 
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Table 1. Criteria for response to rHuEpo 
• Complete response 
- Normalize Hct value 
• Major response : all criteria 
- Disappearance of transfusion needs 
- Hct increment ≥ 6 % 
- Achieve Hct  ≥ 30 % 
• Minor response : any criteria 
- Decrease of transfusion needs  by at least 50 % 
- Hct increment ≥ 6 % but Hct < 30 % 
- Achieve Hct ≥ 30 % but Hct increment < 6 % 
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Table 2. Prediction of response in patients with renal failure treated with rHuEpo. Study by Beguin et al. 28. 







Early Late Overall 
≥ 20 % - - 73 23 96 
< 20 % Normal < 3,500 µg/L 100 0 100 
< 20 % Normal ≥ 3,500 µg/L 38 24 62 
< 20 % High - 0 12 12 
Response = achievement of hematocrit ≥ 30 %. Overall response rate = 77 %. 
sTfR = soluble transferrin receptor. 
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Table 3. Prediction of response in patients with the anemia of cancer treated with rHuEpo. Study by Ludwig 
et al. 14. 





N Yes No 
< 100 ≥ 0.5 15 100 0 
≥ 100 < 0.5 31 6 94 
< 100 < 0.5 
30 70 30 
≥ 100 ≥ 0.5    
Response = Hb increment ≥ 2 g/dL. Overall response rate = 50 %. 
Epo = erythropoietin; Hb = hemoglobin. 
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Table 4. Prediction of response in patients with the anemia of cancer not receiving chemotherapy and treated 
with rHuEpo. Study by Henry et al. 33. 





N Yes No 
≥ 0.5 ≥ 40,000 11 91 9 
≥ 0.5 < 40,000 14 36 64 
< 0.5 ≥ 40,000 6 17 83 
< 0.5 < 40,000 23 4 96 
Response = hematocrit increment ≥ 6 %. Overall response rate = 31 %. 
Hb = hemoglobin; retic = reticulocyte. 
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Table 5. Prediction of response in patients with the anemia of cancer receiving chemotherapy and treated 
with rHuEpo. Study by Henry et al. 33. 





N Yes No 
≥ 0.5 ≥ 40,000 21 67 33 
≥ 0.5 < 40,000 29 66 34 
< 0.5 ≥ 40,000 20 50 50 
< 0.5 < 40,000 62 48 52 
Response = hematocrit increment ≥ 6 %. Overall response rate = 55 %. 
Hb = hemoglobin; retic = reticulocyte. 
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Table 6. Prediction of response in patients with the anemia associated with multiple myeloma or non-












Yes                      No 
≥ 0.9 - 8 13 87 
< 0.9 < 0.3 6 0 100 
< 0.9 ≥ 0.3 34 88 12 
Response = Hb increment ≥ 2 g/dL. Overall response rate = 65 %. 
O/P Epo = ratio of observed-to-predicted serum erythropoietin; Hb = hemoglobin. 
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Table 7. Prediction of response in patients with the anemia of cancer treated with rHuEpo. Study by Cazzola 












Yes                      No 
≥ 100 - 17 18 82 
< 100 < 25 7 29 71 
< 100 ≥ 25 24 96 4 
Response = hemoglobin increment ≥ 2 g/dL. Overall response rate = 58 %. 
Epo = erythropoietin; sTfR = soluble transferrin receptor. 
 
